-transparent.png){kind=logo}
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) destroys dopamine-containing nigrostriatal neurons and increases the apparent Bmax of both D1 and D2 binding sites in the striatum. However, the changes of Bmax occur at different intervals after the lesion. Up-regulation of D2 sites becomes evident about 3 weeks after the lesion and lasts for about 3 months. In contrast, about 3 months are required for the up-regulation of D1 sites and increased binding is still evident after 5 months.
Related Publications
F B Weihmuller, and
J P Bruno, and
N H Neff, and
M Hadjiconstantinou
October 1997,
The Journal of pharmacology and experimental therapeutics,
F B Weihmuller, and
J P Bruno, and
N H Neff, and
M Hadjiconstantinou
February 1982,
Brain research,
F B Weihmuller, and
J P Bruno, and
N H Neff, and
M Hadjiconstantinou
November 2013,
Neurotoxicity research,
F B Weihmuller, and
J P Bruno, and
N H Neff, and
M Hadjiconstantinou
January 2000,
Journal of neuroscience research,
F B Weihmuller, and
J P Bruno, and
N H Neff, and
M Hadjiconstantinou
April 1992,
Synapse (New York, N.Y.),
F B Weihmuller, and
J P Bruno, and
N H Neff, and
M Hadjiconstantinou
January 1997,
Neurotoxicology and teratology,
F B Weihmuller, and
J P Bruno, and
N H Neff, and
M Hadjiconstantinou
August 2005,
Synapse (New York, N.Y.),
F B Weihmuller, and
J P Bruno, and
N H Neff, and
M Hadjiconstantinou
August 1988,
Brain research bulletin,
F B Weihmuller, and
J P Bruno, and
N H Neff, and
M Hadjiconstantinou
December 2008,
Neuroscience letters,
F B Weihmuller, and
J P Bruno, and
N H Neff, and
M Hadjiconstantinou
May 1985,
Research communications in chemical pathology and pharmacology,
